A similar compensatory increase of LH and FSH levels as mentioned above within a few months after discontinuation of LHRH therapy was detected in Arm B of the SPARE trial, reflecting the clinical scenario of hypergonadotropic hypogonadism. Here, PLOD1 is linked to Hypergonadotropic hypogonadism.